Overview
Metrion Biosciences is a specialized contract research organization (CRO) offering ion channel screening services for drug discovery and safety pharmacology. The company provides high-throughput screening (HTS), automated and manual patch clamp electrophysiology, fluorescence-based assays, and custom cell line generation across cardiac, neuroscience, and pain research targets. With over 250 years of collective ion channel expertise, Metrion delivers customized assays from hit identification through lead optimization and mechanism-of-action studies.
Frequently asked questions
- What ion channel screening platforms does Metrion offer?
- Metrion employs multiple screening platforms including automated patch clamp systems (QPatch 48, QPatch 384, Patchliner), manual patch clamp electrophysiology, fluorescence-based assays (FLIPR Penta, Qube-384), plate-based impedance, and label-free detection methods. These platforms support screening campaigns from hit finding through detailed biophysical characterization and mechanism-of-action studies.
- Does Metrion provide cardiac safety screening?
- Yes, Metrion offers comprehensive cardiac ion channel screening services including GLP-hERG testing and Comprehensive In Vitro Proarrhythmia Assay (CiPA) compliant human cardiac ion channel screening assays. These services support regulatory requirements for cardiac safety profiling of drug candidates.
- Can Metrion generate custom cell lines for specific ion channel targets?
- Yes, Metrion has in-house capabilities to generate and validate novel ion channel cell lines, including complex multi-subunit channels. The company's team has over 30 years of experience in molecular biology and stable cell line generation, enabling development of robust assays that deliver consistent, reproducible, and biologically relevant data.